Contents

Pharmacological Treatment for Anxiety in Children, Adolescents, and/or Young Adults - Cycle 1 2018 .......................................................... 2
Addressing Disparities - Cycle 1 2018 ......................................................... 3
Assessment of Prevention, Diagnosis, and Treatment Options (APDTO) - Cycle 1 2018......... 5
Alzheimer's Drug Discovery Foundation Request for Proposal: Prevention Beyond the Pipeline ........................................................................ 6
Alzheimer's Drug Discovery Foundation Request for Proposal: Program to Accelerate Clinical Trials ........................................................................ 8
Limited PCORI Funding Announcement: Dissemination and Implementation of PCORI-Funded Patient-Centered Outcomes Research Results - Cycle 1 2018 .................................................. 10
Alzheimer's Drug Discovery Foundation Request for Proposal: Drug Discovery .................. 11
Request for Letters of Intent for EvansMDS Strategic Funding Initiative in Myelodysplastic Syndromes: Discovery Research Grants 2018................................................................. 14
International Nut and Dried Fruit Council Foundation Annual Call for Research Projects..... 15
St. Baldrick’s Foundation Spring Grant Cycle ........................................................................ 16
Alzheimer's Drug Discovery Foundation Request for Proposal: Biomarkers Development.... 18
EvansMDS Young Investigator Award Request for Applications ........................................ 19
Partnership for Clean Competition Grants Program .......................................................... 20
2018 Sojourns Scholar Leadership Program ......................................................................... 21
American Association for Cancer Research-Ocular Melanoma Foundation Career Development Award ........................................................................ 22
Cure JM Foundation Grants Program ................................................................................. 23
Michelson Prizes for Human Immunology and Vaccine Research ........................................ 23
Call for Letters of Intent: Dup15q Alliance Research Grant Program .................................. 24
Call for Proposals: Leprosy Research Initiative Budget Round 2019 .................................... 25
Independent Grants for Learning & Change Inflammatory Bowel Disease Fellowships ...... 26
PSC Partners Seeking a Cure Research Grants Program ....................................................... 27
Hereditary Disease Foundation Grants Program ................................................................. 28
Partnership for Clean Competition Micro-Grants Program .................................................. 30
Mobility Unlimited Challenge ................................................................................................. 31
St. Baldrick’s Foundation Fall Grant Cycle ............................................................................. 32
Please note that a faculty member’s research administrator will serve as the liaison on all aspects of the internal application process. If you are unsure of whom to talk to, your department contact can be found at the following link. If you pursue any grant opportunity featured in this report, please contact your research administrator first to formulate a submission plan and timeline.

The UMHS Corporate and Foundation Relations team can assist in this process, including providing direct communication with the funding entity to obtain guidance on project appeal/applicability to the funder, provide examples of previously funded UM proposals, and answer general faculty questions.

Grantor: Patient-Centered Outcomes Research Institute
Grant Opportunity: Research Grants
Keyword: Chronic Diseases; Pediatrics & Child Health; Psychiatric; Research Grant
Award Amount: $15 million
Deadline: February 13, 2018

Pharmacological Treatment for Anxiety in Children, Adolescents, and/or Young Adults - Cycle 1 2018


The Patient-Centered Outcomes Research Institute (PCORI) seeks to fund high-quality clinical studies that compare the effectiveness of two or more pharmacological treatments for moderate to severe anxiety in children, adolescents, and/or young adults (e.g., comparisons of shorter-acting to longer-acting selective serotonin reuptake inhibitors (SSRIs) or comparisons of SSRIs to selective serotonin-norepinephrine reuptake inhibitors (SNRIs)) delivered in conjunction with cognitive behavioral therapy (CBT) or an alternative evidence-based psychological intervention.

For this PFA, PCORI is broadly interested in comparisons that are relevant and applicable to a spectrum of developmental stages represented by patients in the age range of 7 through 25 years. Applicants will be asked to clearly define the specific age range to be studied, and to provide a scientific rationale for the proposed study population.
Each proposed comparator must be clearly defined, evidence-based, and widely available, and applicants should ensure that all comparators are appropriate for the age range and disorder severity of the study population. Studies with a minimum follow-up period of one year from baseline are sought, with two years of follow-up preferred. In addition, all studies funded through this initiative must include robust sample sizes of at least 300 participants, with sufficient power demonstrated to conduct proposed analyses.

The maximum project budget is $15 million in direct costs, with a maximum project duration of five years.

This PFA preannouncement is provided to allow potential applicants additional time to identify collaborators, obtain stakeholder input on the research question, and develop responsive, high-quality proposals. Further details will be available in the full announcement to be released on January 16, 2018.

**Applicant Town Hall Session: January 31, 2018; 12:00 p.m. (ET)**

Letter of Intent (LOI) Deadline: February 13, 2018 by 5 p.m. (ET)

Grantor: Patient-Centered Outcomes Research Institute

Grant Opportunity: Research Grants

Keyword: Chronic Diseases; Disparities; Health Policy & Research; HIV/AIDS; Psychosocial; Public Health; Quality Improvement; Sleep Research; Under-represented Populations

Award Amount: $5 million

Deadline: February 13, 2018

**Addressing Disparities - Cycle 1 2018**


Notice of Upcoming PCORI Funding Announcement

This notice provides information about an upcoming Patient-Centered Outcomes Research Institute (PCORI) funding announcement (PFA), which will be released by PCORI on January 16, 2018. PCORI encourages applications from teams with expertise in patient-centered comparative effectiveness research (CER) focusing on the research areas of interest listed below. These areas of interest would greatly benefit from interventions that aim to reduce health disparities and improve patient-centered outcomes among at least one of the Addressing Disparities target populations.

Please note that for this Cycle 1 2018 funding announcement, we now have two options for direct costs and maximum project periods. Applicants may submit Letters of Intent (LOI) for
either awards of up to $2 million in direct costs over a maximum period of three years or awards up to $5 million in direct costs over a maximum period of four years.

Diagnosis, Initiation of Treatment, and Retention of African Americans and Hispanics/Latinos along the HIV Care Continuum

One in seven people living with HIV are unaware of their infection. Racial and ethnic minorities experience the greatest disparities along the HIV Care Continuum; African Americans and Hispanics/Latinos are the most disproportionately affected by HIV. The incidence rate of HIV infection among African Americans is approximately eight times higher than among whites; moreover, Blacks achieve viral suppression at much lower rates than whites. Hispanics/Latinos accounted for about one quarter of all new diagnoses of HIV in the United States.

Therefore, Addressing Disparities seeks to fund studies comparing the clinical effectiveness of interventions of different models of early detection, identification, treatment, and retention to improve patient-centered outcomes for African Americans and Hispanics/Latinos individuals living with HIV.

Addressing Disparities is particularly interested in, but not limited to, interventions that aim to

- Compare effective community-based or culturally competent HIV care management models to increase early diagnosis and initiation of treatment, linkage, and retention; and
- Compare effective HIV care and treatment models with enhanced behavioral and psychosocial interventions to address stigma, mental health, and self-efficacy; and
- Improve specific HIV care education and training to address provider discrimination and patient mistrust and build relationships between patients and providers.

Interventions to Reduce Disparities in Obstructive Sleep Apnea and Insomnia

An estimated 50-70 million adults in the United States have some form of sleep or wakefulness disorder, including obstructive sleep apnea (OSA) and insomnia. OSA and insomnia are closely associated with health problems and increased risk of serious health consequences, such as cardiovascular disease, type 2 diabetes, and obesity.

A substantial proportion of those affected by OSA and insomnia remain undiagnosed. Prevalence is relatively high among certain racial and ethnic groups; African Americans are the most disproportionately affected and are rarely diagnosed with OSA and insomnia. A higher proportion of African American adults reported sleeping 6 hours or less compared to whites.

Addressing Disparities is particularly interested in, but not limited to, interventions targeting racial and ethnic minority populations that aim to

- Increase screening and monitoring of OSA and insomnia
Compare effective cognitive behavioral therapy and medications

Medication-Assisted Treatment (MAT) Delivery for American Indian/Alaska Native Populations with Opioid Misuse Disorders

Addressing Disparities seeks to fund studies comparing the clinical effectiveness of interventions of different models to increase access to MAT, to improve outcomes for American Indians/Alaska Natives with opioid misuse disorder.

Addressing Disparities is particularly interested in, but not limited to, studies that compare different medications and medication formulations as part of comprehensive MAT Community-based or culturally competent MAT Different psychosocial interventions to address stigma, mental health, and self-efficacy Different MAT education and training approaches for treatment programs serving AI/AN populations to encourage the provision of MAT to treat opioid misuse disorder.

Total Direct Costs: $2 million (small studies) or $5 million (large studies)

Letter of Intent (LOI) Deadline: February 13, 2018 by 5 p.m. (ET)

Grantor: Patient-Centered Outcomes Research Institute

Grant Opportunity: Research Grants

Keyword: Health Policy & Research; Quality Improvement; Research Grant

Award Amount: $5 million

Deadline: February 13, 2018

Assessment of Prevention, Diagnosis, and Treatment Options (APDTO) - Cycle 1 2018


Notice of Upcoming PCORI Funding Announcement

Notice of Changes to Total Direct Costs and Maximum Project Period

The mission of the Patient-Centered Outcomes Research Institute (PCORI) is to improve the quality and relevance of evidence available to help patients, caregivers, clinicians, employers, insurers, and policy makers make informed health decisions.
This notice encourages research institutions or consortiums of institutions with expertise in clinical comparative effectiveness research (CER), patient-centered outcomes research (PCOR), and in particular, research that compares the effectiveness of two or more efficacious strategies for prevention, treatment, screening, diagnosis, or management, to considering submitting Letters of Intent in response to the PCORI Funding Announcement (PFA) that opens on January 16, 2018.

For this PFA, proposed projects should address the comparison of specific clinical services or strategies that are defined clearly and can be replicated in other clinical settings with minimal adaptations or changes. This funding opportunity is broad-based and is not confined to specific clinical services or patient populations. However, the program’s goal is to expand the evidence base that pertains to clinical services that would be chosen by clinicians, patients, and caregivers in usual clinical delivery settings.

This preannouncement of the APDTO PFA is provided to notify potential applicants of the recent changes to total direct costs and the maximum project period. Applicants may submit proposals in the following categories:

Small studies with a maximum project period of 3 years with total direct costs up to $2 million.
Large studies with a maximum project period of 4 years and total direct costs up to $5 million.
Letter of Intent (LOI) Deadline: February 13, 2018 by 5 p.m. (ET)

Grantor: Alzheimer's Drug Discovery Foundation

Grant Opportunity: Research Grants

Keyword: Alzheimer’s Disease & Other Dementias; Basic Science; Chronic Diseases; Drug Discovery & Development; Neurological Disorders; Research Grant

Award Amount: $3 million

Deadline: January 19, 2018; April 13, 2018; July 13, 2018; October 12, 2018

Alzheimer's Drug Discovery Foundation Request for Proposal: Prevention Beyond the Pipeline

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline

The ADDF seeks to support comparative effectiveness research, clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Funding Priorities
Consortium of Cohorts for Alzheimer's Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods, supplements, and drugs. However, high-powered studies are needed—ideally with dose, duration, and responder profiles—in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script.

Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition. Methods may include randomized trials or epidemiology.

Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding drug discovery programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.

Average Duration
- One year for epidemiological analyses
- Varies (multi-year) for clinical trials

Average Award
- $50,000-$100,000 for epidemiological analyses based on scope of research
- Up to $3 million based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

Letter of Intent: January 19, 2018
Letter of Intent: April 13, 2018
Letter of Intent: July 13, 2018
Letter of Intent: October 12, 2018

Grantor: Alzheimer's Drug Discovery Foundation
Grant Opportunity: Program Funding

Keyword: Alzheimer’s Disease & Other Dementias; Basic Science; Chronic Diseases; Drug Discovery & Development; Neurological Disorders; Research Grant

Award Amount: $3 million

Deadlines: January 19, 2018; April 13, 2018; July 13, 2018; October 12, 2018

Alzheimer's Drug Discovery Foundation Request for Proposal: Program to Accelerate Clinical Trials

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact

The goal of this Request for Proposals (RFP) is to increase the number of innovative treatments tested in humans for Alzheimer's disease and related dementias. This program will fund (1) clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); (2) proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs*; (3) regulatory studies for investigational new drug (IND)/clinical trial application (CTA) preclinical packages that are required before testing novel drugs in human subjects.

*Repurposed refers to existing drugs that are approved for other diseases and conditions and repositioned refers to existing drugs that have entered clinical trials for other indications and have not yet been approved.

Funding Priorities

Drug targets: Proposed molecular targets will be evaluated based on the strength of available evidence that links the target to the disease and demonstrates that modulating its biological activity will improve symptoms or modify disease progression. Targets will be assessed based on the following criteria—

Is there human genetic evidence linking the target to the disease?

Is the target expressed in disease-relevant regions of the brain (or where applicable, in the periphery) in humans and/or animal models?

Are there changes in target mRNA/protein expression or activity in human disease specimens, and do they correlate with disease severity and cognitive functions?

Does genetic and/or pharmacological manipulation of the target in disease-relevant in vitro (e.g., primary cultured neurons/glia or cells derived from patient iPSCs) or in vivo models alter disease phenotypes?

Are there direct measures of target engagement that can be used experimentally and in humans?
How is the target more compelling than other related targets that have been tested for the disease?

Current target areas of interest include, but are not limited to:

Neuroprotection
Inflammation
Vascular Function
Mitochondria & Metabolic function
Proteostasis
ApoE
Epigenetics
Synaptic Activity & Neurotransmitters

This RFP does not support anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitors.

Clinical trials: The majority of PACT funding will support early-stage clinical trials in humans including phase 0 micro- or sub-therapeutic-dosing studies, phase 1 safety and pharmacology testing, and phase 2a biomarker-based, proof-of-concept studies. This RFP supports novel, repurposed/repositioned, and natural product approaches.

NEW IN 2018 - Experimental medicine: As part of a new initiative to de-risk novel therapeutic approaches with human data earlier in clinical development, the ADDF will support exploratory studies that demonstrate proof-of-mechanism or proof-of-concept with novel or repurposed/repositioned drugs in patients. In line with the experimental medicine approaches developed by the National Institute of Mental Health, the goal is to validate novel molecular targets in humans and to assess therapeutic interventions in treating Alzheimer's and related dementias using pharmacodynamic outcomes.

Regulatory studies: The PACT RFP provides support for IND-enabling pharmacology and toxicology studies and scale-up, pre-formulation, and GMP manufacture. Funding is available to support the preparation of traditional IND and exploratory IND (eIND) applications. ADDF funding is also available for long-term toxicology studies and GMP manufacture required to move into phase 2 or phase 3 trials.

Priority is given to programs with:

Blood-brain barrier permeability (for CNS-targeted therapies) and dose optimization for the intended route of administration and treatment duration for the drug candidate

Target engagement and efficacy data in relevant animal model(s) with the drug candidate
Strong data packages demonstrating selectivity, microsomal stability, aqueous solubility, plasma protein binding, and CYP profiling of drug candidate

Clinical biomarkers that will directly measure target engagement and can monitor treatment effects in human subjects

Intellectual property (for novel therapeutic approaches)

Strong rationale for the proposed clinical population

Strategies for successful recruitment and retention, with evidence of prior success for recruitment of the proposed population and number (for clinical trial proposals only)

Average Duration: Varies (multi-year) with potential for follow-on funding

Average Award: Up to $3 million based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

Letter of Intent: January 19, 2018
Letter of Intent: April 13, 2018
Letter of Intent: July 13, 2018
Letter of Intent: October 12, 2018

Grantor: Patient-Centered Outcomes Research Institute

Grant Opportunity: Research Grants

Keyword: $1,000,000

Award Amount: Health Policy & Research; Quality Improvement; Research Grant

Deadline: February 13, 2018

Limited PCORI Funding Announcement: Dissemination and Implementation of PCORI-Funded Patient-Centered Outcomes Research Results - Cycle 1 2018

https://www.pcori.org/funding-opportunities/announcement/limited-pcori-funding-announcement-dissemination-and-4

Notice of Upcoming PCORI Dissemination and Implementation Funding Announcement

This advance notice informs applicants of new maximum allowable budget and project periods for projects proposed in response to this PCORI Funding Announcement (PFA). While PCORI still encourages projects at the level of $350,000 and 2 years, we will now accept applications requesting up to $1,000,000 in direct costs and 3 years with clear and adequate justification beginning in Cycle 1 2018. Applicants will indicate the funds requested from PCORI when
submitting their letter of intent (LOI). PCORI will advise applicants who are invited to submit a full application as to the acceptability of the budget proposed in their LOI. Because of the newly increased allowable project budget and project period, submission of “Greater Than” requests for funds and time greater than the standard allowance is no longer necessary and has been removed from this PFA.

In general, adequate justification for requesting larger budgets and/or additional time will include a demonstrable ability to significantly increase the

Reach, to substantially more targeted end users

Generalizability, or the applicability of intervention across different groups, systems, and settings

Uptake, or the use and adoption among more systems, settings, or sites of the evidence proposed for dissemination and implementation

Applicants should note that projects proposing budgets of less than $500,000 in total costs are subject to a shorter, more simplified review and approval process.

This limited PFA is designed to move evidence developed with PCORI research funding toward practical use in improving health care and health outcomes. PCORI will fund projects that aim to disseminate and implement patient-centered comparative clinical effectiveness research (CER) results obtained from PCORI-funded studies.

This limited PFA gives PCORI investigators the opportunity, following the generation of results from their PCORI research award, to propose the next step(s) for making their research results more useful, actionable, accessible, and available to targeted end-users of these findings.

Letter of Intent (LOI) Deadline: February 13, 2018 by 5 p.m. (ET)

Grantor: Alzheimer's Drug Discovery Foundation

Grant Opportunity: Research Grants

Keyword: Alzheimer’s Disease & Other Dementias; Basic Science; Chronic Diseases; Drug Discovery & Development; Neurological Disorders; Research Grant

Award Amount: $600,000

Deadline: January 19, 2018; April 13, 2018; July 13, 2018; October 12, 2018

Alzheimer's Drug Discovery Foundation Request for Proposal: Drug Discovery

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-discovery

The Alzheimer's Drug Discovery Foundation (ADDF) has long recognized the need to bridge the translational funding gap between early-stage drug discovery and clinical development for
Alzheimer’s disease, related dementias, and cognitive aging by supporting promising therapeutic approaches. The ADDF’s Drug Discovery Request for Proposals (RFP) focuses on supporting programs that aim to:

Advance novel lead molecules to the clinical candidate selection stage (defined as compounds suitable for IND-enabling studies); or

Build preclinical evidence in relevant animal models for repurposed/repositioned drugs or natural products

Repurposed refers to existing drugs that are approved for other diseases and conditions and repositioned refers to existing drugs that have entered clinical trials for other indications and have not yet been approved.

Funding Priorities

Drug targets: Proposed molecular targets will be evaluated based on the strength of available evidence that links the target to the disease and demonstrates that modulating its biological activity will improve symptoms or modify disease progression. Targets will be assessed based on the following criteria—

Is there human genetic evidence linking the target to the disease?

Is the target expressed in disease-relevant regions of the brain (or where applicable, in the periphery) in humans and/or animal models?

Are there changes in target mRNA/protein expression or activity in human disease specimens, and do they correlate with disease severity and cognitive functions?

Does genetic and/or pharmacological manipulation of the target in disease-relevant in vitro (e.g., primary cultured neurons/glia or cells derived from patient iPSCs) or in vivo models alter disease phenotypes?

Are there direct measures of target engagement that can be used experimentally and in humans?

How is the target more compelling than other related targets that have been tested for the disease?

Current target areas of interest include, but are not limited to:

Neuroprotection

Inflammation

Vascular Function

Mitochondria & Metabolic function

Proteostasis

APOE
Epigenetics

Synaptic Activity & Neurotransmitters

This RFP does not support anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitors.

Stage of discovery: This RFP aims to support in vivo pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies for novel therapeutics, including small molecules and biologics (e.g., antibodies, oligonucleotides, peptides, gene therapy), and for repurposed/repositioned drugs or natural products. Priority is given to novel drug programs that—

Identified a lead molecule or series with in vitro potency (including secondary screens in relevant cell models), selectivity, and toxicity data

Assessed the chemical structure of leads for structural liabilities

Conducted in vitro ADME (absorption, distribution, metabolism, excretion) characterization (e.g., solubility, microsomal stability, Caco-2, MDCK, CYP profiling)

Possess novel composition of matter intellectual property

Priority is given to repurposed/repositioned drug programs that—

Evaluated known side effects of the drug and how well they would be tolerated by the intended clinical population

Identified a supplier that will provide sufficient quantities of the drug or compound to complete the study aims

Demonstrate plans to develop novel intellectual property around the repurposing/repositioning strategy

For in vivo efficacy studies proposals should—

Demonstrate blood-brain barrier penetration (if the intended target is in the CNS)

Justify dosing administration and regimen with in vivo PK/PD data

Include measures of target engagement

This RFP does NOT support target identification, target validation, assay development, high-throughput and high-content screening, and lead optimization.

Average Duration: One year with potential for follow-on funding. Multi-year proposals can be considered.

Average Award: $150,000-$600,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

Upcoming Deadlines
Letter of Intent: January 19, 2018
Letter of Intent: April 13, 2018
Letter of Intent: July 13, 2018
Letter of Intent: October 12, 2018

Grantor: Edward P. Evans Foundation
Grant Opportunity: Research Grants
Keyword: Basic Science; Cancer; Chronic Diseases; Hematology; Research Grant
Award Amount: $400,000
Deadline: January 31, 2018

Request for Letters of Intent for EvansMDS Strategic Funding Initiative in Myelodysplastic Syndromes: Discovery Research Grants 2018

http://evansmds.org/funding-information/

The Edward P. Evans Foundation is a non-profit Charitable Trust dedicated to funding research on Myelodysplastic Syndromes (MDS) through its EvansMDS initiative. We are seeking to fund the discovery of new knowledge that will lead to the development of better MDS therapies and ultimately, disease cures. EvansMDS is conducting this competitive grant program to identify and fund collaborative, transformative, high impact research into the etiology, pathogenesis, and treatment of MDS. Priority will be given to projects that directly examine key features of MDS rather than general concepts in leukemia, hematopoiesis, aging or immunology.

Discovery Research Grants (DRGs) - EvansMDS will offer several individual research grants of up to $200,000 for one year, potentially renewable for a second year, to fund highly innovative and novel research.

The focus of these awards will be on transformational basic, translational or aspects of clinical research that are directly applicable to the etiology, pathogenesis or treatment of MDS.

The following topics are of specific interest to EvansMDS.

Please note that these are only suggestions-we are most interested in whatever your most exciting ideas might be.

• New targets and antigens that distinguish diseased hematopoietic stem cells from healthy cells.
• Analysis of the progression of clonal hematopoiesis to MDS and strategies to intervene, or prevent the pathogenesis of progression.
• What are the obstacles to early diagnosis, treatment, and the cure of MDS, and how might these obstacles be overcome?

• Supplementary research to better understand or clarify the impact of clinical studies showing significant promise for the treatment of MDS.

$200,000 per year for up to two years

Letters of intent are due January 31, 2018 and will be reviewed by the Reviewing Committee and the Foundation.

Grantor: International Nut and Dried Fruit Council Foundation

Grant Opportunity: Research Grants

Keyword: Basic Science; Research Grant

Award Amount: $352,162

Deadline: January 31, 2018

International Nut and Dried Fruit Council Foundation Annual Call for Research Projects

https://www.nutfruit.org/what-we-do/health-nutrition/funding-opportunities

The International Nut and Dried Fruit Council Foundation (INC) promotes clinical, epidemiological, basic and/or strategic research that may contribute to enhance the understanding of the health effects of nuts and dried fruits.

The INC calls for research projects from researchers from public and private institutions, as well as not-for-profit organizations.

Since the INC represents 17 nuts and dried fruits (namely almonds, apricot kernels, Amazonia (Brazil) nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios, walnuts, peanuts, dates, dried apricots, dried cranberries, dried figs, dried grapes and prunes), INC will only accept research projects with at least 3 nuts OR 3 dried fruits.

INC will not accept scientific studies that mix nuts and dried fruits.

Research proposals can include 3 or more of the above mentioned nuts and dried fruits. However, projects that compare nuts or dried fruits among themselves will not be accepted.

Up to 300,000 EUR is available for this grant. This call is for both co-funded and non co-funded projects.

Research priorities:

Nuts or dried fruits and cognitive function.
Nuts or dried fruits and body weight and adipose tissue distribution.
Combination of nuts or dried fruits and blood pressure, clotting factors and inflammatory markers.
Combination of nuts or dried fruits and glycemic load and/or diabetes.
Nuts or dried fruits in exercise performance.
Nuts or dried fruits and intestinal microbiota.
Nuts or dried fruits and metabolomics.
Nuts or dried fruits as part of a healthy diet.
Intervention trials on relevant clinical end points.
Meta-analysis of clinical trials.
Applications due by: January 31, 2018.

Grantor: St. Baldrick’s Foundation
Grant Opportunity: Research Grants and Program Funding
Keyword: Cancer; Career Development; Chronic Diseases; Pediatric Cancers; Pediatrics & Child Health; Research Grant
Award Amount: $330,000
Deadline: January 31, 2018

St. Baldrick’s Foundation Spring Grant Cycle

https://www.stbaldricks.org/for-researchers
The St. Baldrick’s Foundation works hard to be sure that every dollar makes the biggest impact possible in childhood cancer research.
Current funding priorities are divided into four categories:
• New discovery research
• Translational research and early phase clinical trials
  • Phase III clinical trials & infrastructure support of participating institutions (primarily the fall grant cycle)
  • Education of new pediatric oncology researchers
In addition to research to understand the biology of childhood cancers and discover leads to more effective treatments, topics of interest include, but are not limited to:

• Adolescents & young adults

• Survivorship, outcomes, and quality of life

• Supportive care

• Epidemiology and pediatric cancer predispositions

• Precision medicine

• Alternative & complementary therapies

• St. Baldrick’s Scholars: This career development award is to help develop the independent research of highly qualified individuals still early in their careers (no more than seven years as a faculty member, post-fellowship). With up to $110,000/year, three-year minimum, with an opportunity for two additional years, this award is for a Scholar’s salary & benefits only; adjustments may be allowed if the Scholar receives other funds after applying, upon Foundation approval.

• St. Baldrick’s International Scholars: This three-year award, with an option for two additional years based on progress, is available to train researchers from low- and middle- income countries (according to classification made by the World Bank) to prepare them to fill specific stated needs in an area of childhood cancer research, with a commitment to then continue with research in their home country.

• Research Grants: These one-year grants are for specific research projects which are hypothesis driven and may be laboratory, clinical or epidemiological research. While the average grant is $100,000 or less, the proposed budget must be realistic for the project.

• Supportive Care Research Grants: These are for research projects which are hypothesis-driven and focus on areas related to the supportive care of children and adolescents with cancer. Applications are accepted from Ph.D. and D.N.P. holders. Examples include studies related to symptom clusters, patient-reported outcomes or quality of life, health communication, health promotion, and psychosocial support across the trajectory from diagnosis to survivorship or end-of-life care. While the average grant is $50,000 or less, the proposed budget must be realistic for the project.

Letter of Intent due by January 31, 2018

Grantor: Alzheimer's Drug Discovery Foundation

Grant Opportunity: Research Grants

Keyword: Alzheimer’s Disease & Other Dementias; Basic Science; Chronic Diseases; Neurological Disorders; Research Grant
Award Amount: $300,000

Deadlines: January 19, 2018; April 13, 2018; July 13, 2018; October 12, 2018

Alzheimer's Drug Discovery Foundation Request for Proposal: Biomarkers Development

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers

This Request for Proposals (RFP) seeks to support the development and validation of biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease and related dementias. This includes companion biomarkers for specific clinical-stage therapies and biomarkers with broader applicability across trials and therapeutic targets.

Funding Priorities

Neuroimaging: Positron emission tomography (PET) ligands for target engagement and pharmacodynamic measurements of novel and repurposed therapeutics, and novel magnetic resonance imaging (MRI) methods to measure structural, blood flow, and white matter changes in the brain

Cerebrospinal fluid (CSF) and blood-based biomarkers: Multiplex ELISA or mass spectrometry of specific target(s) or transcriptomics, proteomics, metabolomics, or lipidomics signatures

Functional activity measures: Electroencephalogram (EEG), magnetoencephalography (MEG), transcranial magnetic stimulation (TMS)

Other novel approaches that are supported by compelling evidence

Biomarker targets: Current biomarker target areas of interest include, but are not limited to—

Neuroinflammation

Synaptic Integrity and/or Activity

Vascular Injury & Blood-Brain Barrier Integrity

Mitochondria & Metabolic function

Calcium Regulation

Proteostasis

Oxidative Stress

White Matter Changes

The ADDF has limited interest in funding measures of cognition and function, as well as CSF assays of Aβ and tau levels.

Expectations: Priority is given to projects that—
Validate biomarkers previously identified in samples from well-characterized human subjects

Focus on biomarkers with a rational biological connection to the disease process and are supported by a reasonable body of preliminary data

Use validated methods for quantifying and qualifying biomarkers. Developing novel technologies is a lower priority

Average Duration: 1–2 years with potential for follow-on funding

Average Award: $150,000-$300,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

Deadlines:
Letter of Intent: January 19, 2018
Letter of Intent: April 13, 2018
Letter of Intent: July 13, 2018
Letter of Intent: October 12, 2018

Grantor: Edward P. Evans Foundation

Grant Opportunity: Career Development

Keyword: Basic Science; Cancer; Career Development; Chronic Diseases; Hematology; Research Grant

Award Amount: $250,000

Deadline: January 31, 2018

EvansMDS Young Investigator Award Request for Applications

http://evansmds.org/funding-information/

The Edward P. Evans Foundation is a non-profit Charitable Trust dedicated to funding research on Myelodysplastic Syndromes (MDS) through its EvansMDS initiative.

We fund and promote collaboration among leading investigators working on the most promising science so that we might discover new knowledge that will enable cures for MDS.

The Edward P. Evans Foundation has created the EvansMDS Young Investigator Award to help develop the next generation of research leaders who will blaze a path toward finding these cures. We are targeting support for promising candidates committed to the study of the biology, pathogenesis, and treatment of MDS as they make their transition to independent investigators. We recognize that securing independent funding is often challenging during this period of career
development. Our goal is to facilitate this transition and promote the entry of new investigators into the MDS field.

We are offering $125,000 per year for up to two years to defray the costs of salary and supplies as well as introduction of the successful recipients to the growing community and fellowship of MDS investigators supported by EvansMDS.

We do not place any exclusivity restrictions on the funding of this award. As an additional incentive, we offer recipients maximal flexibility to apply for, and receive additional awards from EvansMDS or other parties during the period of EvansMDS Young Investigator Award funding.

$125,000 per year for up to two years

Applications are due January 31, 2018 and will be reviewed by a panel of MDS experts and the Foundation.

Grantor: Partnership for Clean Competition
Grant Opportunity: Research Grants
Keyword: Kinesiology or Sports Medicine; Research Grant
Award Amount: $225,000 (?)
Deadlines: March 1, 2018; July 1, 2018; November 1, 2018

Partnership for Clean Competition Grants Program

http://www.cleancompetition.org/programs/grants-program/

PCC-supported research contributes to a movement in addressing doping’s root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC’s current research priorities:

Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances.

Developing testing protocols to detect designer substances used for doping purposes.

Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG.
Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

There is no maximum amount for PCC funding, though the average funding amount is $225,000. Pre-Applications are due March 1st, July 1st, and November 1st of each year.

Grantor: Cambia Health Foundation
Grant Opportunity: Career Development
Keyword: Career Development; Pain & Palliative Care
Award Amount: $180,000
Deadline: February 1, 2018

2018 Sojourns Scholar Leadership Program

https://www.cambiahealthfoundation.org/sojourns/sojourns-scholar-leadership-program.html

The Sojourns Scholar Leadership Program is an initiative designed to identify, cultivate and advance the next generation of palliative care leaders. The program seeks to include physicians, nurses, social workers, physician assistants, chaplains, psychologists, pharmacists and other emerging health system leaders by investing in their professional development. Sojourns Scholars receive $180,000 in funding ($90,000/year over a two-year grant) to conduct an innovative and impactful project in the field of palliative care and execute a leadership development plan designed to support growth as a national leader in the field.

Goals of Program

Identify outstanding emerging leaders who are physicians, nurses, social workers, physician assistants, chaplains, psychologists, pharmacists and other emerging health system leaders committed to improving access to, knowledge about, and quality of palliative care.

Invest in leadership development, enabling Scholars to use their expertise and influence to create system and policy changes in palliative care locally, regionally and nationally.

Develop the professional visibility and advance the palliative care expertise of the Sojourns Scholars, enhancing their ability to advance the field.

Program Components

A two-year clinical, educational, policy, advocacy, research or systems change project.
An individualized leadership development plan to catalyze and enhance the Sojourns Scholar’s emergence and effectiveness as a national leader.

Annual Sojourns Scholar Leadership Summit.

Mentorship from a member of the National Advisory Committee.

Participation as a member of the Sojourns Scholars community of peers.

Letter of Intent (LOI) due by February 1, 2018 at 12:00 p.m. PST

Grantors: American Association for Cancer Research and the Ocular Melanoma Foundation

Grant Opportunity: Career Development

Keyword: Cancer; Career Development; Chronic Diseases; Research Grant; Vision, Optometry, Ophthalmology

Award Amount: $150,000

Deadline: January 31, 2018

American Association for Cancer Research-Ocular Melanoma Foundation Career Development Award

http://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=13#.WjAhWDeIZhPa

The AACR-Ocular Melanoma Foundation Career Development Award represents a joint effort to encourage and support junior faculty to conduct ocular/uveal melanoma research and establish a successful career path in ophthalmology, ocular oncology, uveal melanoma biology, or a similar field. Eligibility is limited to junior faculty who, at the start of the grant term, will have completed their most recent doctoral degree or medical residency within the past 11 years. The research proposed for funding must be translational or clinical in nature and must have direct applicability and relevance to ocular/uveal melanoma.

The grant provides $150,000 over two years for expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs associated with graduate students' education and training), or research assistants; research/laboratory supplies; equipment; publication charges for manuscripts that pertain directly to the funded project; and other research expenses.

AACR requires applicants to submit an electronic application by 1:00pm, Eastern Time on Wednesday, January 31, 2018, using the proposalCENTRAL website at https://proposalcentral.altum.com.
Cure JM Foundation

Grant Opportunity: Research Grants
Keyword: Chronic Diseases; Rare or Orphan Diseases; Research Grant; Rheumatology
Award Amount: $150,000
Deadline: May 15, 2018

Cure JM Foundation Grants Program

http://www.curejm.org/research/funding.php

The mission of Cure JM Foundation is to find better treatments and a cure for Juvenile Myositis, and to improve the lives of families affected by JM. With this mission in mind, Cure JM has developed an annual grant program to help fund promising avenues of research into the causes and treatment of juvenile dermatomyositis and juvenile polymyositis.

Letters of Intent and application deadlines for the 2018 Cure JM grant cycle have been announced, with Letters of Intent due May 15 and full applications June 15. The LOI is only to allow for the organization of the review process, and all projects submitting an LOI will be permitted to submit a full application.

Cure JM grants are made in concert with the Childhood Arthritis and Rheumatology Research Alliance (CARRA).

Letter of Intent Deadline: May 15, 2018

Michelson Medical Research Foundation and the Human Vaccines Project

Grant Opportunity: Infectious Disease; Research Prize; Vaccine
Keyword: Prizes
Award Amount: $150,000
Deadline: February 12, 2018

Michelson Prizes for Human Immunology and Vaccine Research

http://www.humanvaccinesproject.org/MichelsonPrizes/

The Michelson Medical Research Foundation together with the Human Vaccines Project has established the Michelson Prizes for Human Immunology and Vaccine Research — Two $150K Prizes for Young Investigators
The Michelson Prizes aim to support young investigators applying innovative research concepts and disruptive technologies to significantly advance the development of future vaccines and immunotherapies for major global diseases.

Two investigators, under the age of 35, who demonstrate significant potential to execute pioneering ideas will each be awarded a $150,000 prize. Applicants need to show how they are going beyond conventional approaches in their field and clearly articulate how their contribution will have a lasting impact on human immunology and vaccine research.

Applicants from disciplines across the biomedical, bioengineering and computer science fields are encouraged.

Pre-application Due Date: February 12, 2018

Grantor: Dup15q Alliance
Grant Opportunity: Research Grants
Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Rare or Orphan Diseases; Research Grant
Award Amount: $100,000
Deadline: February 1, 2018

Call for Letters of Intent: Dup15q Alliance Research Grant Program

https://www.dup15q.org/research/grants-and-funding/dup15q-alliance-research-grant-program-letter-of-intent-submission/

Dup15q Alliance invites submission of Letters of Intent for the Dup15q Alliance Research Grant Program. All proposals must be scientifically linked to the Dup15q syndrome.

The Dup15q Alliance Research Grant Program encourages applications from investigators within the first few years of establishing their laboratories and from established investigators venturing into new projects focused on Dup15q syndrome.

Research projects should address one of the following four high-priority areas:

Understanding phenotypic heterogeneity in Dup15q, i.e., contributions of genetic, biologic, or environmental factors.

Defining the neurobiological and neurophysiological underpinnings of the Dup15q using cellular, animal or human systems.

Dup15q disease models, whether cell-based, tissue-based, or animal models.
Developing and validating clinical biomarkers or patient-reported outcome measures, particularly those that assess disease burden or stratify an individual’s risk of progression or developing specific manifestations of Dup15q syndrome.

Duration: up to two years

Budget limits: Maximum total costs of $50,000 per year ($100,000 total) direct costs only.

Due Date: Feb 1, 2018

Grantor: Leprosy Research Initiative

Grant Opportunity: Research Grants

Keyword: Chronic Diseases; Infectious Disease; Public Health; Rare or Orphan Diseases; Research Grant

Award Amount: $88,147

Deadline: February 28, 2018

Call for Proposals: Leprosy Research Initiative Budget Round 2019

https://www.leprosyresearch.org/research/how-we-work

The Leprosy Research Initiative (LRI) is pleased to announce a call for proposals for funding commencing in 2019. LRI funds research with a focus on leprosy – including research applications combining leprosy with other neglected tropical diseases (NTDs) or other diseases that share cross-cutting issues with leprosy. Proposals addressing any of the five research priorities are eligible for funding in this call.

Research priorities:

In 2011, the ILEP Technical Commission produced a research agenda of 20 topics for leprosy. On the basis of this agenda and results from a survey among field partners (including persons affected by leprosy) 5 research areas were selected as main priorities. The projects should aim to:

1. Early Detection: Promote and enable early detection of leprosy

2. Nerve Function Impairment and Reactions: Promote prevention, early detection and effective treatment of nerve function impairment (NFI) and reactions

3. Inclusion: Promote inclusion of persons affected by leprosy in society

4. Prevention of Disability: Improve the coverage of prevention of disability activities and their integration in national programmes and integrated wound and limb care programmes
5. Interrupt Transmission: Test methods and tools to interrupt the transmission and incidence of leprosy, including increasing the coverage of effective contact management and chemoprophylaxis

There is no budget ceiling for the current call. By way of guidance: projects LRI has funded in the past years had an average annual budget of €30,000 (ranging from €10,000 to €75,000) – although in exceptional cases higher annual budgets have been accepted. The duration of proposals should not exceed four years.

A LoI may be submitted at any time during the year, using the format available on the LRI site. However, to be considered for the budget round 2019, the LoI should be submitted by February 28th, 2018.

Grantor: Pfizer

Grant Opportunity: Fellowships

Keyword: Chronic Diseases; Inflammatory Bowel Disease; Post-Doctoral Fellowship

Award Amount: $80,000

Deadline: February 16, 2018

Independent Grants for Learning & Change Inflammatory Bowel Disease Fellowships

https://www.pfizer.com/purpose/medical-grants/request-proposals

The intent of this Request for Proposal (RFP) is to encourage organizations with an active inflammatory Bowel Disease (IBD) fellowship program to submit a proposal.

The purpose of the Fellowship Program grant is to support the continued training of fellows focused on research and clinical practice.

Organizations seeking funding must submit proposals describing the strength of their program in support of clinical training and research.

Clinical area: Inflammatory Bowel Disease

Specific Area of Interest: It is our intent to support institutions with IBD fellowship programs that have a strong focus on clinical practice, research, and education to further the understanding of IBD.

Please note this is not meant to support a 3 year gastroenterology fellowship.

Grants will be awarded based on the strength of the requesting organization’s ability to provide training and guidance to the fellow.
Additionally, programs who have secured partial funding from other sources will be given priority.

New IBD fellowship programs are encouraged to apply.

Individual requests for fellowship grants up to $80,000 for one year will be considered.

Funding is to be used as salary supplement for a fellow at the recipient organization

Applications due: Feb 16, 2018

Grantor: PSC Partners Seeking a Cure

Grant Opportunity: Research Grants

Keyword: Basic Science; Career Development; Chronic Diseases; Rare or Orphan Diseases; Research Grant

Award Amount: $80,000

Deadline: March 25, 2018

PSC Partners Seeking a Cure Research Grants Program

http://pscpartners.org/research-grants/grant-application/

PSC Partners offers grants to conduct research that addresses an important and novel, basic or clinical research question related to PSC and closely associated diseases (such as inflammatory bowel diseases (IBD), ulcerative colitis (UC) or Crohn’s disease) as they relate to PSC. Our Research Grants Program seeks to encourage investigators to conduct research in promising new areas, with the goal that data generated will lead to federal (NIH) or external international funding.

Grant Amounts

Research grant funding is limited to $30,000 per year for 2 years ($60,000 total). However, focused proposals with smaller budget requests will also be considered.

The Young Investigator Award totals $80,000 ($40,000 per year, paid over 2 years).

PSC Partners Seeking a Cure is delighted to provide a Young Investigator Award to promising researchers who are at the early stages of their research career and are interested in clinical, translational or basic research on Primary Sclerosing Cholangitis. The Young Investigator Award is a research grant in the amount of $80,000 ($40,000 per year, paid over 2 years).

PSC Partners Seeking a Cure is particularly interested in funding research projects that:
foster interdisciplinary collaborations and the sharing of resources as a means of accelerating progress in PSC research

If the proposal includes a specific plan for sharing of results (collaborations) and resources (such as DNA), this will result in a more favorable review.

have the potential to discover a cure for PSC

identify novel therapies that may significantly delay time to liver transplantation, prevent disease recurrence following liver transplantation, and/or improve the quality of life of those with PSC

aim to identify the gene-environment interactions contributing to disease initiation and progression

explore PSC-related diseases (IBD, UC, and Crohn’s disease) in ways that they impact, enable, or perhaps cause PSC

address PSC in children

will be complementary to the goals and objectives of the International PSC Study Group, including investigation of the functional roles of genes associated with susceptibility to and severity of PSC

address the mechanisms of PSC pathogenesis and colorectal and cholangiocarcinoma carcinogenesis, as well as strategies for prevention

PSC Partners recognizes that studies with animal models may be appropriate to address these fundamental questions. Proposals that have little relevance to PSC will not be considered for funding.

The deadline for submission of 2018 grant proposals is March 25, 2018.

Grantor: Hereditary Disease Foundation

Grant Opportunity: Research Grants and Postdoctoral Fellowships

Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Neurological Disorders; Neuromuscular Disorders; Post-Doctoral Fellowship; Rare or Orphan Diseases; Research Grant

Award Amount: $75,000

Deadline: February 1, 2018

Hereditary Disease Foundation Grants Program

http://www.hdfoundation.org/funding-the-future-2/
The Hereditary Disease Foundation provides funding for research that advances the discovery and development of treatments for Huntington’s disease and other brain disorders. We are passionate about finding and funding the most innovative, creative and paradigm-changing research possible. The data generated with HDF funding often allows researchers to get initial findings that help them apply successfully for larger, long-term funding from other funding agencies, including the National Institutes of Health.

The Foundation’s current focus is on 1) modifier studies - on DNA repair pathways, protein degradation and other modifiers of phenotype and age of onset and 2) research mechanisms of HD neurodegeneration and biomarkers and therapy for HD-induced neurodegeneration.

Types of Funding

The Basic Research Grants Program: Supports projects contributing to identifying and understanding the fundamental defects in Huntington’s disease.

Postdoctoral Fellowships: These postdoctoral fellowships are intended to cultivate interest in Huntington’s disease research by bright young scientists. Fellowships are granted to those who possess imagination, rigor, creativity and spirit to push forward toward a cure for HD and ensure that these learning can be applied to other brain diseases.

The Hereditary Disease Foundation is currently accepting Letters of Intent (LOIs) for Grants and Postdoctoral Fellowships. The HDF provides funding for research that advances the discovery and development of treatments and a cure for Huntington’s disease and other brain diseases.

The process of applying for funding for either the Basic Research Grants Program or the Postdoctoral Fellowship Program starts with an applicant’s submission of a Letter of Intent.

Grants are up to $75,000 for one year

Postdoctoral Fellowships follow NIH Guidelines for Postdoctoral Trainees and Fellows: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-134.html. Fellowships are for two years; the second year is contingent on submission and acceptance of satisfactory progress reports.

The HDF gives highest priority to providing funding to investigators enthusiastic about launching a career in Huntington's disease research. These include postdoctoral fellows and new assistant professors.

Deadline for Submission of Letters of Intent: February 1

Grantor: Partnership for Clean Competition
Grant Opportunity: Research Grants
Keyword: Kinesiology or Sports Medicine; Research Grant
Award Amount: $75,000
Deadline: Rolling

Partnership for Clean Competition Micro-Grants Program

http://www.cleancompetition.org/programs/micro-grants-program/

The rapidly changing landscape of performance enhancing substances necessitates efficient responses from organizations protecting the integrity of sport. The Micro-Grant Program was developed by the PCC to quickly fund quality research projects which fill immediate gaps in anti-doping knowledge and/or gather preliminary data to strengthen a regular cycle PCC Grant application or re-submission.

Projects eligible for micro-grant funding will satisfy the following guidelines:

The applicant seeks to solve an acute anti-doping problem or gather preliminary data for a larger scale PCC Grant.

The research requires fewer than 6 months to complete.

The research requires less than $75,000 in funding.

The research does not require IRB approval, or IRB approval has been obtained ahead of applying for a PCC Micro-Grant.

The application is not designed to supplement existing funds from a primary funder. If the PCC is not the sole funder of the project, the rationale behind seeking multiple funding sources must be provided within the application.

The project’s investigators represent a single institution. If investigators from multiple institutions wish to collaborate on a PCC Micro-Grant, a letter of support or cooperation from the secondary institution must accompany the application.

Projects which enhance knowledge surrounding (suspected or known) performance enhancing substances, provide reference materials, collect and test samples from critical populations, or justify/impact anti-doping policies are excellent candidates for a PCC Micro-Grant. However, any research solving time-sensitive anti-doping challenges will be considered. For examples of micro-grants the PCC has previously funded, please visit our funded research page.

Applicants need not wait for a formal funding cycle to apply for a PCC Micro-Grant – requests are accepted year-round and may take as little as one week to approve.

Grantor: Mobility Unlimited Challenge

Grant Opportunity: Research Challenge

Keyword: Assistive Technology; Devices & Robotics; Neuromuscular Disorders; Prizes
The Mobility Unlimited Challenge supports radical improvements in the mobility and independence of people with lower-limb paralysis through smarter assistive technology.

The Mobility Unlimited Challenge aims to harness creative thinking from across the world to accelerate innovation and encourage collaboration with end-users, resulting in devices that will integrate seamlessly into users’ lives and environments, enabling greater independence and increased participation in daily life.

We’re looking for teams with engineering, software, design and data science expertise. But more importantly, we’re looking for teams who put end-users at the heart of everything they do. That means engaging people with lower-limb paralysis from the outset to develop devices that best meet their needs.

Devices might incorporate Artificial Intelligence that will help predict user intent. Or long-life, fast charging batteries that will give people the freedom to move for days or weeks at a time without worrying about power. Or a re-engineered exoskeleton that will redefine assistive mobility. Or something the world hasn't even realized is possible.

7 February 2018: Deadline to apply for a Discovery Award.
11 April 2018: Ten Discovery Award winners receive $50k each.
Funds used to develop applications to become a Finalist.
15 August 2018: Deadline to apply to become a Finalist in the Challenge.
Unnecessary to be a Discovery Awardee to become a Finalist.
14 January 2019: Five Finalist teams announced.
Each receives a $500k Finalist Development Grant.
September 2020: 1 winning team receives a $1m Prize.

Grantor: St. Baldrick’s Foundation
Grant Opportunity: Research Fellowships and Program Funding
Keyword: Cancer; Chronic Diseases; Pediatric Cancers; Pediatrics & Child Health; Post-Doctoral Fellowship
Award Amount: $50,000
Deadline: July 13, 2018

St. Baldrick’s Foundation Fall Grant Cycle

https://www.stbaldricks.org/for-researchers

- Infrastructure Grants: These grants are not for a specific research project, but rather for resources to allow more research to be done. They support institutions with the potential for more participation in childhood cancer clinical trials, but which currently lack necessary resources (primarily support for Clinical Research Associates). Preference is given to institutions with high needs and low philanthropic support in geographical areas where St. Baldrick’s funds are raised. Institutions which do not currently receive other St. Baldrick’s grants are also given preference. (Average grant will be $25,000–$50,000.)

- St. Baldrick’s Fellows (Note: due date for 2018 has changed): The St. Baldrick’s Foundation funds years 3–5 of a pediatric oncology research fellowship with an opportunity for one additional year of funding. This mechanism is designed to support a Fellow’s salary and benefits only. The St. Baldrick’s Foundation encourages applications from institutions with fellowship programs that have not previously received St. Baldrick’s funding for this grant mechanism. Letter of Intent due by July 13, 2018; applications due by August 31, 2018.

Grantor: American-Italian Cancer Foundation
Grant Opportunity: Postdoctoral Fellowships
Keyword: Basic Science; Cancer; Chronic Diseases; Post-Doctoral Fellowship

Award Amount: $40,000
Deadline: February 28, 2018

American-Italian Cancer Foundation International Post-Doctoral Research Fellowship Program

http://www.americanitaliancancer.org/

Eligibility for AICF fellowships is limited to Italian citizens applying for fellowships in the United States, and to US citizens applying for fellowships in Italy. Applicants cannot have resided in the Country where their fellowship will take place for more than a year from the due date of the application.

Eligible applications for an AICF Fellowship include proposals for basic or translational cancer research, as well as clinical research.
Fellowship stipends of $40,000 for the 2018-19 period are meant to cover most living expenses of the awarded candidate.

Deadline is February 28, 2018.

Grantor: National Tay-Sachs & Allied Diseases Association

Grant Opportunity: Research Grants

Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Rare or Orphan Diseases; Research Grant

Award Amount: $40,000

Deadline: January 12, 2018

National Tay-Sachs & Allied Diseases Association Request for Proposals

https://www.ntsad.org/index.php/research/for-researchers

A major element of NTSAD’s mission is to lead the fight to treat and cure Tay-Sachs, Canavan and related genetic diseases; therefore, NTSAD is committed to funding research projects that advance this mission.

We are soliciting proposals for innovative research projects that involve basic research, translational studies or clinical studies in the following diseases: Tay-Sachs, GM-1, Sandhoff, and Canavan disease. CTSF’s funding interests will be only in Tay-Sachs disease. Basic research and translational studies should generate strong preliminary data to enable future major funding by other third parties. Projects may be in such areas as drug delivery to the brain, new animal models designed to facilitate translational research and drug discovery, assay development for drug screening, substrate reduction, stem cells, molecular chaperones, gene therapy, and biomarkers, as well as exploring other novel therapeutic strategies.

In addition to soliciting proposals for novel research projects, we strongly encourage applicants to submit proposals that address one or more of the following: understanding disease progression and natural history as well as unmet needs from a patient perspective across the severity spectrum of any given indication, development of patient registries, translational biomarkers with clinical utility, measurable and clinically meaningful efficacy endpoints for clinical trials, clinical research networks, and newborn screening.

Grants will be awarded for an initial period of one year at up to $40,000 direct costs per year (5% indirect cost rate); funding for a second year is predicated by adequate progress during year 1.

The deadline for submission of one-page pre-applications is January 12, 2018.
Grantor: VentureWell
Grant Opportunity: Research Competition
Keyword: Assistive Technology; Devices & Robotics
Award Amount: $25,000
Deadline: February 7, 2018; May 2, 2018

VentureWell E-Team Program

https://venturewell.org/student-grants/

We fund and train student inventors and entrepreneurs who want to address important problems in the world through new technology-based ventures. Our E-Team Program provides funding, immersive workshops, and specialized coaching to student STEM innovators to help them move their inventions into the marketplace.

An E-Team—or Entrepreneur-Team—is a multidisciplinary group of students and faculty working together to bring an invention to market.

What types of projects/products does VentureWell fund?

Some examples include medical or healthcare-related devices; products to aid in poverty alleviation or address basic human needs; and clean/green technologies. We mostly fund physical or engineered products, but have funded software or mobile products that fulfill the other criteria.

E-Team Program stages:

Stage 1: $5,000 + workshop
Stage 2: $20,000 + workshop + coaching
ASPIRE – investment and partnership training

Upcoming deadlines: February 7, 2018; May 2, 2018